Zacks Research Expects Stronger Earnings for Gilead Sciences

Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) - Analysts at Zacks Research lifted their FY2024 earnings per share estimates for Gilead Sciences in a research note issued on Monday, November 4th. Zacks Research analyst E. Bagri now expects that the biopharmaceutical company will post earnings per share of $3.73 for the year, up from their prior estimate of $3.72. The consensus estimate for Gilead Sciences' current full-year earnings is $3.75 per share. Zacks Research also issued estimates for Gilead Sciences' Q2 2025 earnings at $1.72 EPS, FY2025 earnings at $7.18 EPS, Q2 2026 earnings at $1.82 EPS and FY2026 earnings at $7.54 EPS.

Several other equities research analysts have also issued reports on GILD. Leerink Partnrs raised shares of Gilead Sciences from a "hold" rating to a "strong-buy" rating in a research note on Monday, October 21st. Wells Fargo & Company upgraded Gilead Sciences from an "equal weight" rating to an "overweight" rating and upped their price target for the stock from $78.00 to $100.00 in a research note on Monday, October 7th. Royal Bank of Canada reissued a "sector perform" rating and issued a $75.00 price objective on shares of Gilead Sciences in a research note on Tuesday, October 29th. Cantor Fitzgerald reaffirmed a "neutral" rating and set a $70.00 target price on shares of Gilead Sciences in a research report on Monday, September 16th. Finally, Sanford C. Bernstein started coverage on shares of Gilead Sciences in a research report on Thursday, October 17th. They issued an "outperform" rating and a $105.00 price target on the stock. Ten research analysts have rated the stock with a hold rating, eleven have given a buy rating and three have assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $86.85.

Gilead Sciences Stock Performance

GILD stock opened at $91.69 on Thursday. The firm has a 50 day moving average of $84.58 and a two-hundred day moving average of $74.67. Gilead Sciences has a 12 month low of $62.07 and a 12 month high of $91.98. The company has a market capitalization of $114.15 billion, a price-to-earnings ratio of 111.82, a P/E/G ratio of 3.13 and a beta of 0.17. The company has a quick ratio of 0.95, a current ratio of 1.14 and a debt-to-equity ratio of 1.18.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last announced its quarterly earnings results on Thursday, August 8th. The biopharmaceutical company reported $2.01 EPS for the quarter, beating the consensus estimate of $1.61 by $0.40. The business had revenue of $6.95 billion during the quarter, compared to analysts' expectations of $6.64 billion. Gilead Sciences had a return on equity of 29.34% and a net margin of 3.79%.

Insider Activity

In related news, insider Johanna Mercier sold 29,357 shares of the company's stock in a transaction dated Thursday, September 12th. The shares were sold at an average price of $83.78, for a total value of $2,459,529.46. Following the sale, the insider now owns 78,127 shares of the company's stock, valued at $6,545,480.06. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. In other news, insider Merdad Parsey sold 2,000 shares of the business's stock in a transaction on Tuesday, October 1st. The shares were sold at an average price of $83.83, for a total value of $167,660.00. Following the sale, the insider now owns 100,189 shares in the company, valued at approximately $8,398,843.87. The trade was a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider Johanna Mercier sold 29,357 shares of the stock in a transaction dated Thursday, September 12th. The stock was sold at an average price of $83.78, for a total transaction of $2,459,529.46. Following the sale, the insider now owns 78,127 shares of the company's stock, valued at $6,545,480.06. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 36,847 shares of company stock worth $3,033,340. 0.29% of the stock is currently owned by corporate insiders.

Institutional Trading of Gilead Sciences

Several large investors have recently added to or reduced their stakes in the company. Vanguard Group Inc. grew its position in Gilead Sciences by 2.6% during the 1st quarter. Vanguard Group Inc. now owns 114,732,575 shares of the biopharmaceutical company's stock worth $8,404,161,000 after acquiring an additional 2,910,147 shares during the last quarter. Swedbank AB bought a new stake in shares of Gilead Sciences during the first quarter worth $134,489,000. International Assets Investment Management LLC increased its stake in shares of Gilead Sciences by 8,238.4% in the third quarter. International Assets Investment Management LLC now owns 1,642,504 shares of the biopharmaceutical company's stock valued at $137,708,000 after buying an additional 1,622,806 shares in the last quarter. Capital Research Global Investors raised its holdings in shares of Gilead Sciences by 2.7% in the first quarter. Capital Research Global Investors now owns 61,246,366 shares of the biopharmaceutical company's stock valued at $4,486,296,000 after buying an additional 1,589,240 shares during the last quarter. Finally, Pacer Advisors Inc. lifted its position in Gilead Sciences by 24.7% during the 2nd quarter. Pacer Advisors Inc. now owns 7,889,663 shares of the biopharmaceutical company's stock worth $541,310,000 after buying an additional 1,564,792 shares in the last quarter. 83.67% of the stock is owned by institutional investors.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.